Published in Blood Weekly, April 27th, 2006
The increase in demand for Grifols products, principally plasma derivatives such as immunoglobulin intravenous (IgIV) in international markets explains this significant increase in turnover. In 2005, 70% of sales from the group came from international markets and reached EUR 367 million, increasing 22.3% from the previous year. The United States generated EUR 149 million, growing 62.4% compared to 2004. Turnover in Spain was EUR 157 million, 11.3% higher than 2004.
The bioscience division, which includes all products and activities related to plasma for...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.